Extracellular Vesicles from Thapsigargin-Treated Mesenchymal Stem Cells Ameliorated Experimental Colitis via Enhanced Immunomodulatory Properties

Therapeutic applications of extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs) have attracted considerable attention because of their immunomodulatory properties against immune-mediated, inflammatory diseases. Here, we demonstrated enhanced immunomodulatory properties of EVs sec...

Full description

Bibliographic Details
Published in:	Biomedicines
Main Authors:	Hansol Joo, Mi-Kyung Oh, Ji Yeon Kang, Hyun Sung Park, Dong-Hoon Chae, Jieun Kim, Jong-Hee Lee, Hee Min Yoo, Uimook Choi, Do-Kyun Kim, Hakmo Lee, Sungjoo Kim, Kyung-Rok Yu
Format:	Article
Language:	English
Published:	MDPI AG 2021-02-01
Subjects:	EVs mesenchymal stem cells thapsigargin immunomodulatory property indoleamine 2,3-dioxygenase (IDO) colitis model
Online Access:	https://www.mdpi.com/2227-9059/9/2/209

Similar Items

Indoleamine-2,3-dioxygenase: An important controller in maintaining mesenchymal stem cell-mediated immunomodulatory homeostasis
by: Yufei Hui, et al.
Published: (2025-07-01)

Inhibitory effects of flavonoids isolated from Sophora flavescens on indoleamine 2,3-dioxygenase 1 activity
by: Mincheol Kwon, et al.
Published: (2019-01-01)

The Two Sides of Indoleamine 2,3-Dioxygenase 2 (IDO2)
by: Chiara Suvieri, et al.
Published: (2024-11-01)

The Relationships among Tryptophan, Kynurenine, Indoleamine 2,3-Dioxygenase, Depression, and Neuropsychological Performance
by: Knut A. Hestad, et al.
Published: (2017-10-01)

IDO Expression in Cancer: Different Compartment, Different Functionality?
by: Annabel Meireson, et al.
Published: (2020-09-01)

The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1
by: Eleonora Panfili, et al.
Published: (2023-04-01)

Expression of Indoleamine 2,3-Dioxygenase Induced by IFN-γ and TNF-α as Potential Biomarker of Prostate Cancer Progression
by: Irina Banzola, et al.
Published: (2018-05-01)

Indoleamine 2,3 dioxygenase (IDO) level as a marker for significant coronary artery disease
by: Nattawut Wongpraparut, et al.
Published: (2021-07-01)

DSS-induced colitis activates the kynurenine pathway in serum and brain by affecting IDO-1 and gut microbiota
by: Li-Ping Zhao, et al.
Published: (2023-01-01)

IDO-Mediated Immune and Metabolic Dysregulation in Schwann Cells Exposed to <i>Mycobacterium leprae</i>
by: Atta Ur Rahman, et al.
Published: (2025-10-01)

Alzheimer’s disease-specific transcriptomic and epigenomic changes in the tryptophan catabolic pathway
by: Kyonghwan Choe, et al.
Published: (2024-11-01)

Indoleamine 2,3-Dioxygenase (IDO) Activity: A Perspective Biomarker for Laboratory Determination in Tumor Immunotherapy
by: Pengbo Yang, et al.
Published: (2023-07-01)

Indoleamine 2,3-dioxygenase 1 alters the proportions of B cell subpopulations in the microenvironment of acute myeloid leukemia
by: Yu Yao, et al.
Published: (2025-04-01)

Significance of Indoleamine 2,3-Dioxygenase Expression in the Immunological Response of Kidney Graft Recipients
by: Krzysztof Wiśnicki, et al.
Published: (2022-09-01)

Design, Synthesis and Biological Evaluation of Phenyl Urea Derivatives as IDO1 Inhibitors
by: Chuan Zhou, et al.
Published: (2020-03-01)

Immunohistochemical Features of Indoleamine 2,3-Dioxygenase (IDO) in Various Types of Lymphoma: A Single Center Experience
by: Mee-seon Kim, et al.
Published: (2020-05-01)

Indoleamine 2,3-dioxygenase 1 expression predicts cholangiocarcinoma patient survival
by: Mallika Naeklang, et al.
Published: (2026-06-01)

GSH-responsive polymeric micelles-based augmented photoimmunotherapy synergized with PD-1 blockade for eliciting robust antitumor immunity against colon tumor
by: Chenlu Huang, et al.
Published: (2024-09-01)

Gut-heart immuno-metabolic disruption associated with inflammaging and subclinical coronary artery disease in people with HIV on antiretroviral therapy
by: Ana-Karla Diego-Matos, et al.
Published: (2026-04-01)

Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?
by: Cemil Bilir, M.D., et al.
Published: (2017-07-01)

Antiviral activity of interferon-γ involved in impaired immune function in infectious diseases
by: Sucher Robert, et al.
Published: (2013-12-01)

Immunohistochemical Detection of Indoleamine 2,3-Dioxygenase in Spontaneous Mammary Carcinomas of 96 Pet Rabbits
by: Sandra Schöniger, et al.
Published: (2024-07-01)

Dynamic change of IDO1 activity predicts survival in patients with unresectable stage III NSCLC and chemoradiotherapy
by: Linfang Wu, et al.
Published: (2022-08-01)

Nanodelivery Optimization of IDO1 Inhibitors in Tumor Immunotherapy: Challenges and Strategies
by: Jiang K, et al.
Published: (2024-08-01)

Immunomodulatory Factors in Primary Endometrial Cell Cultures Isolated from Cancer and Noncancerous Human Tissue–Focus on RAGE and IDO1
by: Joanna Tkaczuk-Włach, et al.
Published: (2021-04-01)

IDO‐1 Promotes Pulmonary Vascular Remodeling Via Kynurenine Pathway in Pulmonary Arterial Hypertension
by: Zongye Cai, et al.
Published: (2025-08-01)

Tryptophan deficiency induced by indoleamine 2,3‐dioxygenase 1 results in glucose transporter 1‐dependent promotion of aerobic glycolysis in pancreatic cancer
by: Heng Liang, et al.
Published: (2024-05-01)

Extracellular spermidine attenuates tryptophan breakdown in mitogen-stimulated peripheral human mononuclear blood cells
by: Karg Cornelia A., et al.
Published: (2025-10-01)

TRYPTOPHAN AND INDOLEAMINE-2,3-DIOXYGENASE (IDO) IN PATHOGENESIS OF IMMUNOSUPPRESSIVE CLINICAL CONDITIONS
by: V. A. Kozlov, et al.
Published: (2017-07-01)

Increased Indoleamine 2,3-Dioxygenase 1 (IDO-1) Activity and Inflammatory Responses during Chikungunya Virus Infection
by: Thiara Manuele Alves de Souza, et al.
Published: (2022-04-01)

Indoleamine 2,3-Dioxygenase Is Involved in Interferon Gamma’s Anti-BKPyV Activity in Renal Cells
by: Tony Fiore, et al.
Published: (2020-08-01)

Indoleamine 2,3- Dioxygenase: A Novel Immunotherapeutic Target for Osteosarcoma
by: Asim Farooq, et al.
Published: (2022-09-01)

Wine and Grape Juice Modulate Interferon-y-induced Neopterin Production and Tryptophan Degradation in Human PBMC
by: Neurauter Gabriele, et al.
Published: (2004-02-01)

Involvement of the tryptophan-kynurenine pathway in the pathogenesis of autoimmune diseases
by: A-Yuan Chen, et al.
Published: (2025-10-01)

IDO1 modulates pain sensitivity and comorbid anxiety in chronic migraine through microglial activation and synaptic pruning
by: Jiao Hu, et al.
Published: (2025-02-01)

Thapsigargin induces non-apoptotic programmed cell death in RBL-1 cells
by: Steiner Philip, et al.
Published: (2024-01-01)

Exploring a repurposed candidate with dual hIDO1/hTDO2 inhibitory potential for anticancer efficacy identified through pharmacophore-based virtual screening and in vitro evaluation
by: Nourhan M. Aboomar, et al.
Published: (2024-04-01)

Kynurenines as a Novel Target for the Treatment of Inflammatory Disorders
by: Adrian Mor, et al.
Published: (2024-07-01)

Changes and imbalance of Th1 and Th2 immune response in pediatric patients with seasonal allergic conjunctivitis
by: Palabiyik-Yucelik Saziye Sezin, et al.
Published: (2025-07-01)

Pharmacological Targets of Kaempferol Within Inflammatory Pathways—A Hint Towards the Central Role of Tryptophan Metabolism
by: Stefanie Hofer, et al.
Published: (2020-02-01)